Andrew E. Blum

601 total citations
18 papers, 301 citations indexed

About

Andrew E. Blum is a scholar working on Surgery, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Andrew E. Blum has authored 18 papers receiving a total of 301 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Surgery, 8 papers in Molecular Biology and 5 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Andrew E. Blum's work include Esophageal Cancer Research and Treatment (7 papers), Esophageal and GI Pathology (3 papers) and Connexins and lens biology (2 papers). Andrew E. Blum is often cited by papers focused on Esophageal Cancer Research and Treatment (7 papers), Esophageal and GI Pathology (3 papers) and Connexins and lens biology (2 papers). Andrew E. Blum collaborates with scholars based in United States, Netherlands and India. Andrew E. Blum's co-authors include George Dubyak, Amitabh Chak, Ronald J. Przybylski, Nicholas J. Shaheen, Prasad G. Iyer, Yonne Peters, Rebecca C. Fitzgerald, Rhonda F. Souza, Massimiliano di Pietro and Oliver Pech and has published in prestigious journals such as Gastroenterology, Cancer Research and The American Journal of Gastroenterology.

In The Last Decade

Andrew E. Blum

17 papers receiving 296 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Andrew E. Blum United States 8 124 120 86 45 34 18 301
Benjamin K. Eschle United States 9 28 0.2× 201 1.7× 45 0.5× 45 1.0× 12 0.4× 14 370
Jonathan Bruno United States 8 20 0.2× 222 1.9× 28 0.3× 25 0.6× 46 1.4× 11 362
Mourad Métioui Belgium 8 43 0.3× 238 2.0× 19 0.2× 38 0.8× 112 3.3× 9 377
Solange Vidal Switzerland 5 35 0.3× 144 1.2× 14 0.2× 37 0.8× 8 0.2× 8 213
Wee Teik Keng Malaysia 11 100 0.8× 183 1.5× 50 0.6× 23 0.5× 4 0.1× 20 420
Scott D. Auerbach United States 10 45 0.4× 353 2.9× 148 1.7× 15 0.3× 4 0.1× 12 531
S. Emami France 10 93 0.8× 183 1.5× 25 0.3× 53 1.2× 3 0.1× 27 349
Masumi Miura United States 7 67 0.5× 224 1.9× 70 0.8× 19 0.4× 11 0.3× 7 393
Mitsunori Kawato Japan 9 36 0.3× 165 1.4× 47 0.5× 41 0.9× 12 0.4× 11 377
Amanda Boyce United States 6 16 0.1× 103 0.9× 56 0.7× 43 1.0× 65 1.9× 9 345

Countries citing papers authored by Andrew E. Blum

Since Specialization
Citations

This map shows the geographic impact of Andrew E. Blum's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrew E. Blum with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrew E. Blum more than expected).

Fields of papers citing papers by Andrew E. Blum

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrew E. Blum. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrew E. Blum. The network helps show where Andrew E. Blum may publish in the future.

Co-authorship network of co-authors of Andrew E. Blum

This figure shows the co-authorship network connecting the top 25 collaborators of Andrew E. Blum. A scholar is included among the top collaborators of Andrew E. Blum based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrew E. Blum. Andrew E. Blum is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Singh, Salendra, et al.. (2025). LincPRKD: A Long Intergenic Noncoding RNA Activated in Gastric Cancer. Gastro Hep Advances. 4(5). 100618–100618.
2.
Greer, Katarina B., et al.. (2024). Nonendoscopic Screening for Barrett's Esophagus and Esophageal Adenocarcinoma in At-Risk Veterans. The American Journal of Gastroenterology. 120(3). 545–553. 4 indexed citations
3.
Singh, Salendra, Amitabh Chak, David G. Beer, et al.. (2023). Discovery and Initial Characterization of Long Intergenic Noncoding RNAs Associated With Esophageal Adenocarcinoma. Gastroenterology. 165(2). 505–508.e7. 2 indexed citations
4.
Garman, Katherine S., Gary W. Falk, Dawn Dawson, et al.. (2023). Genetic Defect in Submucosal Gland–Associated Caveolin-3: A New Paradigm in Esophageal Adenocarcinoma Risk. Gastroenterology. 165(6). 1561–1564.e3. 1 indexed citations
5.
Joseph, Peronne, Salendra Singh, Adam Kresak, et al.. (2022). The Ephrin B2 Receptor Tyrosine Kinase Is a Regulator of Proto-oncogene MYC and Molecular Programs Central to Barrett’s Neoplasia. Gastroenterology. 163(5). 1228–1241. 12 indexed citations
6.
Blum, Andrew E., Salendra Singh, Adam Kresak, et al.. (2022). HNF4A Defines Molecular Subtypes and Vulnerability to Transforming Growth Factor β-Pathway Targeted Therapies in Cancers of the Distal Esophagus. Gastroenterology. 163(5). 1457–1460. 3 indexed citations
7.
Cioffi, Gino, Apoorva K. Chandar, Jill S. Barnholtz‐Sloan, et al.. (2021). Age of diagnosis in familial Barrett’s associated neoplasia. Familial Cancer. 21(1). 115–120. 3 indexed citations
8.
Blum, Andrew E., Lakshmeswari Ravi, Adam Kresak, et al.. (2019). Systems Biology Analyses Show Hyperactivation of Transforming Growth Factor-β and JNK Signaling Pathways in Esophageal Cancer. Gastroenterology. 156(6). 1761–1774. 36 indexed citations
9.
Peters, Yonne, Nicholas J. Shaheen, Amitabh Chak, et al.. (2019). Barrett oesophagus. Nature Reviews Disease Primers. 5(1). 35–35. 96 indexed citations
10.
Miller, Jane S., Andrew E. Blum, Paul Reddell, et al.. (2019). Dose Characterization of the Investigational Anticancer Drug Tigilanol Tiglate (EBC-46) in the Local Treatment of Canine Mast Cell Tumors. Frontiers in Veterinary Science. 6. 106–106. 28 indexed citations
11.
Sharma, Anamay N., Ashley L. Faulx, & Andrew E. Blum. (2018). Severe CMV Gastritis Associated With Pembrolizumab Therapy. The American Journal of Gastroenterology. 113(Supplement). S1486–S1487. 1 indexed citations
12.
Chan, Megan, Andrew E. Blum, Apoorva K. Chandar, et al.. (2018). Association of sporadic and familial Barrett's esophagus with breast cancer. Diseases of the Esophagus. 31(4). 1 indexed citations
13.
Blum, Andrew E., Yan Guo, Lakshmeswari Ravi, et al.. (2016). RNA Sequencing Identifies Transcriptionally Viable Gene Fusions in Esophageal Adenocarcinomas. Cancer Research. 76(19). 5628–5633. 20 indexed citations
14.
Blum, Andrew E., et al.. (2016). Vedolizumab for the Treatment of Crohnʼs Disease: Experience in an Inflammatory Bowel Disease Clinical Practice. The American Journal of Gastroenterology. 111. S276–S276. 2 indexed citations
15.
Blum, Andrew E., et al.. (2015). Effect of protein aggregates on characterization of FcRn binding of Fc-fusion therapeutics. Molecular Immunology. 67(2). 616–624. 12 indexed citations
16.
Blum, Andrew E., et al.. (2009). Extracellular osmolarity modulates G protein-coupled receptor-dependent ATP release from 1321N1 astrocytoma cells. American Journal of Physiology-Cell Physiology. 298(2). C386–C396. 31 indexed citations
17.
Blum, Andrew E., et al.. (2008). Rho-family GTPases modulate Ca2+-dependent ATP release from astrocytes. American Journal of Physiology-Cell Physiology. 295(1). C231–C241. 48 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026